When does the palivizumab patent expire?
Palivizumab is protected by a mix of patent terms and exclusivity rights that can vary by country and by the specific “patent family” being counted (for example, process patents vs. composition-of-matter vs. formulation). The exact expiration date depends on jurisdiction.
What patents protect palivizumab, and what kinds of claims do they cover?
Patents for biologics like palivizumab commonly fall into categories such as:
- Composition-of-matter (the molecule itself or protected variants)
- Manufacturing/process (how the antibody is made)
- Formulation and delivery (how it’s prepared/stored/used)
- Later-life improvements (if separate filings exist)
Which of these are still active at any given time is what drives different “expiration” dates people report, especially across regions.
Can biosimilars enter palivizumab before the last patent expires?
Biosimilar launch timing is usually linked to a combination of:
- Patent expiry (and whether any patents are still enforceable)
- Regulatory exclusivity rules (often separate from patents)
- Any litigation outcomes that can delay approval or marketing
So even if a biosimilar could be approved under the regulatory pathway, marketing can still be blocked by active patents.
Why do people see different “expiration dates” for palivizumab?
Differences usually come from:
- Country-by-country patent filing and term differences
- Different patent numbers within the same product portfolio being referenced
- “Earlier” vs “latest” patent in the relevant jurisdictions
- Extensions, supplemental protection, or pediatric/other statutory exclusivities where available
Where can I check the most reliable palivizumab patent expiration dates?
For the most accurate, jurisdiction-specific answer, you typically need to check:
- The US: Orange Book listing for reference product status where applicable, and patent listings tied to that biologic’s regulatory entry
- Europe: national/regional patent databases and any SPC (supplementary protection) records
- Other countries: local patent registers
If you tell me your country, I can narrow it down
Patent expiration is jurisdiction-specific. If you share the country (for example, US, UK, EU, Canada, Japan) and whether you care about biosimilar/market entry timing or just the core patent expiry, I can help you identify which patent/exclusivity set would control the answer.
Sources
I can’t cite specific palivizumab patent documents or expiration dates because no source material was provided with your request. If you paste links (e.g., patent numbers, a listing page, or a regulator entry), I can synthesize the exact expiry dates and what they mean for biosimilar entry.